



# Chapter 2

## An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood

Imran Uddin, Kroopa Joshi, Theres Oakes, James M. Heather, Charles Swanton, on behalf of the TRACERx consortium, and Benny Chain

### Abstract

The T cell receptor repertoire provides a window to the cellular adaptive immune response within a tumor, and has the potential to identify specific and personalized biomarkers for tracking host responses during cancer therapy, including immunotherapy. We describe a protocol for amplifying, sequencing, and analyzing T cell receptors which is economical, robust, sensitive, and versatile. The key experimental step is the ligation of a single-stranded oligonucleotide to the 3' end of the T cell receptor cDNA, which allows easy amplification of all possible rearrangements using only a single set of primers per locus, while simultaneously introducing a unique molecular identifier to label each starting cDNA molecule. After sequencing, this molecular identifier can be used to correct both sequence errors and the effects of differential PCR amplification efficiency, thus producing a more accurate measure of the true T cell receptor frequency within the sample. This method has been applied to the analysis of unfractionated human tumor lysates, subpopulations of tumor-infiltrating lymphocytes, and peripheral blood samples from patients with a variety of solid tumors.

**Key words** T cell receptor, High-throughput sequencing, Lung cancer, Adaptive immune response, Immunotherapy

---

## 1 Introduction

The recent dramatic successes of checkpoint immunotherapy for several cancers have prompted a reexamination of the T cell immune response to tumor antigens. One approach to evaluating and tracking this response is by studying the T cell receptor (TCR) repertoire. The TCR is generated during differentiation in the

---

TRACing Cancer Evolution through therapy (Rx). Full list of members in [Appendix](#).

Imran Uddin and Kroopa Joshi have contributed equally to this work.

Alejandro López-Soto and Alicia R. Folgueras (eds.), *Cancer Immunosurveillance: Methods and Protocols*, Methods in Molecular Biology, vol. 1884, [https://doi.org/10.1007/978-1-4939-8885-3\\_2](https://doi.org/10.1007/978-1-4939-8885-3_2), © Springer Science+Business Media, LLC, part of Springer Nature 2019

thymus by a process of somatic DNA recombination of the  $\alpha$  and  $\beta$  (or in a minor population the  $\gamma$  and  $\delta$ ) TCR genes. The imprecise rearrangement of either V and J segments or V, D, J segments of alpha and beta chains, respectively, gives rise to a huge number of different complementarity determining region 3 (CDR3) sequences, which determine the antigen specificity of individual T cell clones.

Although the mechanisms for the generation of diversity have been studied in great detail, the very diversity of the sequences coding for the receptors prevented a global analysis of the repertoire of B or T cell antigen receptors using conventional DNA-sequencing techniques. The rapid advances in high-throughput DNA sequencing (HTS) over the past decades and specifically the introduction of reliable massively parallel technologies (reviewed in [1]) have opened the way for increasingly robust and extensive BCR and TCR repertoire studies. Repertoire analysis provides a powerful tool for the study of both fundamental and translational immunology, and is increasingly being used to study the anti-tumoral immune response to solid cancers [2–7]. Since each T cell and its descendants express a unique rearranged receptor, TCR sequencing provides an opportunity to precisely “track” T cell clones through a period of time, for example, following immunotherapeutic intervention [8–13]. Moreover, TCR sequencing has proven valuable in the context of hematological malignancies for early and sensitive detection of minimal residual disease (MRD) in patients with acute or chronic lymphoblastic leukemia [14, 15], providing information that is critical for the clinical management of these patients.

Despite its promise, repertoire analysis provides many experimental and computational challenges, for which a variety of solutions have been proposed [16–19]. Logistic considerations such as cost, ease of use, robustness, and versatility, as well as more scientific issues such as accuracy and coverage, may contribute to which solution is optimal for different laboratories. We present here an experimental pipeline for TCR repertoire analysis, which we and others are using for the analysis of repertoires in solid tumors and blood. A computational pipeline with which to analyze the data is presented elsewhere [20, 21]. The defining feature of the protocol is that it uses single-stranded cDNA ligation mediated by T4 RNA ligase, which we have demonstrated to have a high efficiency, in order to incorporate unique molecular identifiers (UMIs) [22–24]. UMIs can be used both for sequence error correction and to mitigate for inherent PCR heterogeneity [25]. This allows quantitative estimates of TCR gene abundance. We have successfully used this method to characterize the TCR repertoire from tumor-infiltrating lymphocyte (TIL) suspensions and unfractionated frozen tumor tissue from non-small cell lung carcinoma (NSCLC), metastatic melanoma, and bladder cancer.

---

## 2 Materials

Prepare any primers or reagents that require the addition of water using RNase-free water. Store all reagents according to manufacturer's instructions.

1. The full list of oligonucleotides is shown in Table 1. We order all oligonucleotides from Sigma-Aldrich (now Merck). We use HPLC purified grade unless otherwise indicated. All oligonucleotides are stored at  $-20^{\circ}\text{C}$ , and defrosted on wet ice before use. Avoid repeat freeze thawing by using small aliquots of all reagents.
2. Collagenase (*Clostridium histolyticum*, Sigma).
3. RNase-free water.
4. Wet Ice.
5. 96-Well PCR Plate, Semi-Skirted with Straight Edges (StarLab).
6. RQ1 RNase-free DNase kit including 10 $\times$  buffer, DNase, and DNase stop buffer (Promega).
7. dNTP Mix (10 mM each) (Thermo Fisher Scientific).
8. Superscript III Reverse transcriptase kit including first strand buffer, DTT, and reverse transcriptase (Thermo Fisher Scientific). Superscript IV has also been used successfully.
9. RNasin Ribonuclease Inhibitor (Promega). Alternative RNase inhibitors such as RNaseOUT (Thermo fisher Scientific) can also be used.
10. MinElute Spin kit including Buffer PB, Buffer PE, and MinElute columns (Qiagen).
11. Molecular grade Ethanol.
12. T4 RNA Ligase 1 (ssRNA Ligase) kit including T4 RNA Ligase reaction buffer, Adenosine-5'-Triphosphate (ATP), and Polyethylene glycol (PEG) 8000 50% (New England Biolabs).
13. 10 mg/mL bovine serum albumin (BSA; New England Biolabs).
14. Hexamine Cobalt (III) Chloride (HCC) stock solution (100 mM, can be stored at room temperature; Sigma-Aldrich).
15. An aqueous solution containing 1 mg/mL BSA and 10 mM HCC. To make 10  $\mu\text{L}$  of solution, mix 8  $\mu\text{L}$  of RNase-free water, 1  $\mu\text{L}$  of HCC stock (Subheading 2, item 14), and 1  $\mu\text{L}$  of BSA stock (Subheading 2, item 13).
16. Agencourt AMPure XP beads (Beckman Coulter).

**Table 1**  
**Oligonucleotide sequences for TCR library preparation**

Name	Sequence		Protocol step	Modification
	Human			
Alpha_RC2	GAGTCTCTCAGCTGGTACACG		3.4	
Beta_RC2	ACACAGCGACCTCGGGTGGAA		3.4	
6N_I8.1_6N_I8.1_SP2	<sup>a</sup> P-NNN NNN ATCACGAC NNN NNN ATCACGAC AGA TCG GAA GAG CAC ACG TCT GAA CTC CAG-C3		3.5	5'phosphate; 3'C3 spacer
Alpha RC1	ATCTACACTACGGCAGGGTCAGGGTTCTGGATAT		3.6	
Beta RC1.1 <sup>b</sup>	TACACTGGTGGGAACACACCTTGTTCAGGTCCTC		3.6	
Beta RC1.2 <sup>b</sup>	ATCTACACTGGTGGGAACACAGTTTTTCAGGTCCTC		3.6	
SP1-6N-Ix-1-aRC1 <sup>c,d</sup>	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNATCAGCACGG CAGGGTCAGGGTCTCGATAT		3.7	
SP1-6N-Ix-1-bRC1.1 <sup>b,c,d</sup>	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNATCAGGGGTG GGAACACCTTGTTCAGGTCCTC		3.7	
SP1-6N-Ix-1-bRC1.2 <sup>b,c,d</sup>	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNATCAGGGGTG GGAACACGTTTTTTCAGGTCCTC		3.7	
P7-Iy-SP2 <sup>e</sup>	CAAGCAGAAGACGGGCATACGAGATATCAGGTGACTGGAGTTCAGACGTG TGCTCTCCGATC		3.7	
SP1-P5 <sup>f</sup>	AATGATACGGCGACCAACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC		3.5	

SP2 <sup>f</sup>	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT	3.6
P5 <sup>f</sup>	AATGATACGGCGACCACCGAGATCTACACT	3.8
P7 <sup>f</sup>	CAAGCAGAAGACGGCATACGAGAT	3.8

<sup>a</sup>The ligation oligonucleotide is phosphorylated at the 5' terminus, and blocked using a C3 spacer at the 3' terminus

<sup>b</sup>Two beta RC1 primers are required, as there are two isoforms of the beta constant region gene in the human genome. The two primers should be synthesized separately, and then made up as a stock solution containing 10 μM of each primer

<sup>c</sup>"N" represents a position at which any base can be inserted randomly

<sup>d</sup>The "x" refers to the index number. Underlined bases represent a representative index sequence, and can be substituted by any of the Illumina indices. The indices allow multiple libraries to be combined for sequencing, and then deconvoluted for analysis

<sup>e</sup>The "y" refers to the index number. We have used "y" to indicate the index number, to highlight that the index sequences at the P5 and P7 end of the amplicon can be different, thus allowing many potential combinations of primers to be used. The underlined bases represent a representative index sequence, and can be substituted by any of the Illumina indices

<sup>f</sup>The SP1 sequence is used by the Illumina sequencing protocol to initiate read 1. The SP2 sequence is used to initiate reads 2 (index only) and 3 (reverse). P5 and P7 sequences are adaptors necessary for binding of the DNA fragment to the flow cell

17. Phusion® High-Fidelity DNA Polymerase kit including HF Buffer (New England BioLabs).
18. MicroAmp™ Fast Optical 96-Well Reaction Plate with bar-code (Thermo Fisher Scientific).
19. SYBR™ Green I Nucleic Acid Gel Stain, 10,000× concentrate in DMSO (ThermoFisher). Make a stock solution by diluting this 1:100 in DMSO and store in the dark at  $-20^{\circ}\text{C}$ .
20. ROX Reference Dye (Thermo Fisher Scientific).
21. Micro-Pipettes (10  $\mu\text{L}$ , 20  $\mu\text{L}$ , 200  $\mu\text{L}$ , and 1000  $\mu\text{L}$ ).
22. 1.5 mL DNase/RNase-free, low-retention microcentrifuge tubes (Thermo Scientific).
23. PCR Plate seals (4titude); used for sealing the plates prior to loading onto the thermocycler (e.g., Ligation, PCR1 and PCR2).
24. Plate seals (StarLab); cheaper plate seals used to seal the plate for steps not involving thermocycler (e.g., purifications, or bead elutions).
25. Optical Plate seals (Applied Biosystem); used for real-time PCR.
26. StarChill PCR Rack, Purple/Pink (StarLab).
27. Desktop centrifuge/plate centrifuge.
28. Electric Pipette.
29. 96-well Thermocycler.
30. 96-well Magnetic Stand (e.g., Invitrogen).
31. 96-well qPCR Thermocycler.
32. Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific).
33. Qubit RNA BR Assay Kit (Thermo Fisher Scientific).
34. Qubit Assay Tubes (Thermo Fisher Scientific).
35. Qubit Fluorometer (ThermoFisher, using components 30–32). Alternative fluorometric DNA quantitation technologies could also be used, if they are of equivalent or have greater sensitivity and accuracy.
36. High-Sensitivity D1000 ScreenTape (Agilent Technologies).
37. High-Sensitivity D1000 Reagents (Agilent Technologies).
38. RNA ScreenTape (Agilent Technologies).
39. RNA ScreenTape Sample Buffer (Agilent Technologies).
40. Tape station TapeStation (all one word) 2200 or 4200 (Agilent Genomics, using reagents 34–37). Alternative nucleic acid quality control platforms could be used (e.g., Bioanalyzer, Agilent Technologies), providing they accurately determine the length of input DNA libraries and/or RNA samples.
41. DNase I (Roche).


42. GentleMACS Dissociator (Miltenyi).
43. Ficoll-paquePlus (GE Healthcare).
44. RNeasy Mini or micro kits (Qiagen).
45. AllPrep DNA/RNA Mini kit (Qiagen).

### 3 Methods

#### 3.1 Isolation of Lymphocytes from Human Tumor Samples

A diagrammatic overview of the pipeline is shown in Fig. 1.

The protocols for lymphocyte extraction and RNA extraction (Subheading 3.2) have been developed using resected tissue from non-small cell lung carcinoma (NSCLC) collected as part of the Lung TRACERx study [26, 27]. The same methods have also been used with core tissue biopsies. For lymphocyte extraction, fresh tissue samples are digested with collagenase (100  $\mu\text{L}/\text{mL}$ ) and DNase I (0.2 mg/mL) at 37 °C for 30 min. Samples can be subsequently homogenized using a gentleMACS Dissociator and filtered through a 0.7- $\mu\text{m}$  cell mesh. Leukocytes are enriched by gradient centrifugation with Ficoll-paque PLUS (GE Healthcare) and resuspended in 350  $\mu\text{L}$  of RLT buffer (or 75  $\mu\text{L}$  RLT buffer if  $\leq 1 \times 10^5$  cells) (buffer in RNeasy kits, Subheading 2, item 44). Following resuspension, samples should be mixed by either vortexing or pipetting, and subsequently cryopreserved at  $-80$  °C. RNA



**Fig. 1** Diagrammatic overview of library preparation. Numbers in brackets refer to numbered sections in text

can also be successfully extracted from cryopreserved TILs or PBMC following washing of cryopreserved cells post thawing and resuspension in RLT buffer.

### **3.2 Extraction of RNA from Snap-Frozen Tumor Tissue, Frozen TILs, or PBMC**

Extraction of RNA from snap-frozen tumor tissue involves firstly the homogenization of tumor tissue using a handheld homogenizer followed by RNA extraction using an AllPrep DNA/RNA Mini kit. Extracted RNA is eluted in 200  $\mu$ L of water. RNA extraction from frozen TILs or PBMC is performed following density-gradient centrifugation using Ficoll-Paque PLUS. Following lysis in RLT buffer, RNA is extracted from TILs or PBMC using the Qiagen RNeasy kits. The RNA is eluted in 14  $\mu$ L (Qiagen Micro kit is used for fewer than  $5 \times 10^5$  cells) or 30  $\mu$ L (Qiagen mini kit). The RNA is quantified fluorometrically (e.g., using the Qubit with RNA BR reagents) and integrity can be assessed using a Bioanalyzer or Tapestation.

### **3.3 Residual DNA Removal**

Any residual genomic DNA is removed by DNase treatment. The RNA should be diluted as necessary in RNase-free water to give a final volume of 8  $\mu$ L, aiming for a final total amount of 1–1000 ng. For total tumor tissue samples, 500–1000 ng RNA are normally used (we have found 1000 ng to be optimal, where available). If the RNA has been treated with DNase separately (for instance, during RNA extraction), this step is omitted and the protocol starts at Subheading 3.4 with 11  $\mu$ L of total RNA. All RNA and reagents are kept on wet ice during the protocol.

1. Place a 96-well plate on a 96-well Chill rack.
2. Transfer the required amount of RNA (max 8  $\mu$ L) into a well of a 96-well plate. For concentrated samples, make up to 8  $\mu$ L with RNase-free water.
3. Add 1  $\mu$ L of RQ1 10 $\times$  Buffer and 1  $\mu$ L of RQ1 DNase into each sample, mixing by gentle pipetting.
4. Apply PCR plate seal and centrifuge briefly to ensure all liquids are at the bottom of the well. Place the plate into a 96-well thermocycler at 37 °C for 30 min.
5. Briefly centrifuge to collect condensation and add 1  $\mu$ L of RQ1 DNase Stop buffer to each sample, and reseal.
6. Briefly centrifuge the plate and then place the plate into the thermocycler at 65 °C for 10 min to inactivate the DNase.

### **3.4 Reverse Transcription (see Note 1)**

1. Briefly centrifuge the plate and add 4  $\mu$ L of RNase-free water, 1.5  $\mu$ L of oligonucleotides Alpha RC2 and Beta RC2 (Table 1), and 1.5  $\mu$ L of dNTPs per sample. For  $N$  samples (where  $N > 1$ ), a master mix should be prepared, containing 1.1  $N$  times the volumes above. The mix should be thoroughly mixed by pipetting or vortexing, and then 8.5  $\mu$ L of mix should be added to each sample. Seal the plate.



2. Briefly centrifuge the plate and then place it into the thermocycler at 65 °C for 5 min.
3. Immediately transfer the plate to ice, and leave for at least 1 min.
4. Briefly centrifuge the plate and add 6 µL of 5× FS Buffer, 1.5 µL of 0.1 M DTT, 1.5 µL of RNasin, and 1.5 µL of SS III RT to each sample. For  $N$  samples (where  $N > 1$ ), a master mix should be prepared, containing 1.1  $N$  times the volumes above. The mix should be thoroughly mixed by pipetting or vortexing, and then 10.5 µL of mix should be added to each sample. The total sample volume at this stage should be 30 µL.
5. Briefly centrifuge the plate and then place into the thermocycler at 55 °C for 30 min, followed by 70 °C for 15 min.
6. Briefly centrifuge the plate and add 150 µL of Buffer PB (MinElute kit, Qiagen) to each sample, mixing well. Apply the plate seal and briefly centrifuge the plate.
7. Transfer the sample (180 µL) into a MinElute column (with collection tube). Proceed with DNA purification as detailed in MinElute kit instructions.
8. Elute the purified DNA in 10.5 µL of water (in order to allow the small volume of water enough time to dissolve the DNA leave on filter of the MinElute column for 1 min before centrifugation). Centrifuge the column at  $12,000 \times g$  force for 1 min. Purified cDNA should now be in 10 µL at the bottom of a polypropylene tube. Discard the MinElute column.

### 3.5 Ligation (see Note 2)


1. Transfer 10 µL of cDNA from Subheading 3.3 into a new 96-well plate.
2. Mix 3 µL of T4 RNA ligase buffer, 3 µL of 1 mg/mL BSA/10 mM HCC solution (Subheading 2, item 15), 1 µL of ATP, 1 µL SP2-I8 ligation oligonucleotide, 2 µL of T4 RNA Ligase, and 10 µL of PEG 8000 50% per sample (in that order). For multiple samples make a master mix as above. The PEG solution is very viscous; allow it to first equilibrate to RT, and pipette very slowly with a wide-mouth tip. The mixture should be thoroughly mixed by pipetting to ensure uniformity.
3. Cover the plate with a plate seal, briefly centrifuge, and then place into the thermocycler at 16 °C for 23 h. Inactivate ligase by incubating at 65 °C for 10 min and then store at 4–10 °C until purification (for a maximum of 24 h).
4. Briefly centrifuge the plate and add 70 µL of water to each sample and mix. Seal and briefly centrifuge.
5. Add 50 µL of AMPure XP beads to each sample, mix by pipetting up and down at least ten times (avoid creating bubbles),

and leave at RT for 5 min. Note that the AMPure XP beads should be used at RT; remove from the fridge 30 min prior to use.

6. Briefly centrifuge the plate and then place onto a magnetic stand (*see* Subheading 2) and leave it for two minor until a pellet is formed.
7. Remove the clear liquid from the sample (ensuring the tip of the pipette does not touch the beads, and that no beads are aspirated).
8. Add 300  $\mu\text{L}$  of freshly prepared 80% ethanol to each sample and leave for 30 s at RT. A larger volume is added at this step in order to further dilute the PEG in the ligation.
9. Remove the ethanol, discard and add another 200  $\mu\text{L}$  of 80% ethanol to each sample and leave for 30 s at RT.
10. Remove all ethanol from the sample, ensuring no liquid is left behind in the well.
11. Remove the plate from the magnet and dry at RT for 5 min. Samples can also be dried by placing the plate on a heat block at 37 °C; however, the samples need to be carefully monitored to prevent over drying, which manifests by cracks appearing in the bead pellet.
12. Add 32.5  $\mu\text{L}$  of water into each sample and pipette mix at least ten times. Leave at RT for 2 min.
13. Briefly centrifuge the plate and place onto the plate magnet for 2 min.
14. Transfer 31  $\mu\text{L}$  of the sample into a clean 96-well plate.

### **3.6 First Amplification—PCR 1** (*see Note 3*)

1. Add 10  $\mu\text{L}$  of 5 $\times$  HF Buffer, 2.5  $\mu\text{L}$  of oligonucleotide Alpha RC1 (10  $\mu\text{M}$ , Table 1), 2.5  $\mu\text{L}$  of oligonucleotide Beta RC1 (10  $\mu\text{M}$ ) (which is a premixed equimolar mixture of Beta RC1.1 and 1.2, Table 1), 2.5  $\mu\text{L}$  of oligonucleotide SP2 (10  $\mu\text{M}$ ), 1  $\mu\text{L}$  of dNTPs (10 mM), and 0.5  $\mu\text{L}$  of Phusion Polymerase to each sample. For  $N$  samples (where  $N > 1$ ), a master mix should be prepared, containing 1.1  $N$  times the volumes above. The mix should be thoroughly mixed by pipetting or vortexing, and then 19  $\mu\text{L}$  of mix should be added to each sample. The total sample volume at this stage should be 50  $\mu\text{L}$ .
2. Seal and briefly centrifuge the plate and then place it into the thermocycler, and amplify using the cycler program shown in Fig. 2.
3. Briefly centrifuge the plate and add 40  $\mu\text{L}$  of prewarmed AMPure XP beads into each sample, mix by pipetting at least ten times. Seal and leave at RT for 5 min.
4. Briefly centrifuge the plate and then place onto the Magnetic Stand and leave for two minor until a pellet is formed.



**Fig. 2** PCR 1 thermocycler program setup

- Purify following the procedure described in Subheading 3.5, steps 7–11. Use 200  $\mu\text{L}$  ethanol for each wash step.
- Add 65  $\mu\text{L}$  of water into each sample and pipette mix at least ten times. Seal and leave at room temperature for 2 min.
- Briefly centrifuge the plate and place onto the plate magnet for 2 min.
- Transfer 31  $\mu\text{L}$  of each sample into a fresh 96-well plate and label the plate “Alpha.”
- Transfer another 31  $\mu\text{L}$  of each sample into another fresh 96-well plate and label it “Beta.” The Alpha and Beta samples can be transferred onto the same plate, as long as the two sets of samples are kept physically separate (e.g., Columns 1–6 contain Alpha samples and columns 7–12 contain Beta samples).

### 3.7 Second Amplification—PCR 2 (see Note 4)

- The alpha and beta samples can be processed in parallel. Add 2.5  $\mu\text{L}$  of SP1-6N-Ix-aRC1 (1  $\mu\text{M}$ , Table 1) to each sample in the alpha plate, or 2.5  $\mu\text{L}$  of SP1-6N-Ix-bRC1 to each sample in the beta plate. Note that, as shown in Table 1, SP1-6N-Ix-bRC1 is a premixed equimolar mixture of SP1-6N-Ix-bRC1.1 and SP1-6N-Ix-bRC1.2.

This oligonucleotide introduces a random hexamer at the start of the sequence to augment nucleotide diversity and improve cluster calling during Illumina sequencing. It also introduces a six or eight base pair index read (Ix, which can be chosen from the standard Illumina index sequence sets) which allows multiplexing of many different samples on the same sequencing run.


- Add 2.5  $\mu\text{L}$  of P7-Iy-SP2 (10  $\mu\text{M}$ , Table 1) to each sample. This oligonucleotide introduces an additional six or eight base pair index to allow further multiplexing. Choose different Ix and Iv index pairs for different samples that are to be sequenced

on the same sequencing run. Alpha and beta from the same sample can be indexed with the same index pairs, and separated out at analysis.

3. Add 10  $\mu\text{L}$  of 5 $\times$  HF Buffer, 2.5  $\mu\text{L}$  of SP1-P5 (10  $\mu\text{M}$ , Table 1), 1  $\mu\text{L}$  of dNTPs, and 0.5  $\mu\text{L}$  of Phusion polymerase to each sample. For  $N$  samples (where  $N > 1$ ), a master mix should be prepared, containing 1.1  $N$  times the volumes above. The mix should be thoroughly mixed by pipetting or vortexing, and then 14  $\mu\text{L}$  of mix should be added to each sample. The total sample volume at this stage should be 50  $\mu\text{L}$ .
4. Seal and briefly centrifuge alpha and beta plates, then place into a thermocycler, and amplify using the cycler program shown in Fig. 3.
5. Briefly centrifuge each plate and then add 40  $\mu\text{L}$  of prewarmed AMPure XP beads into each sample, mix by pipetting at least ten times, seal, and leave at RT for 5 min.
6. Briefly centrifuge and then place plate on the Magnetic Stand, and leave for 2 min or until a pellet is formed.
7. Purify following the procedure described in Subheading 3.5, steps 7–11.
8. Elute each sample in 30  $\mu\text{L}$  of water and pipette mix at least ten times. Seal and leave at RT for 2 min.
9. Briefly centrifuge the plate and place onto the plate magnet for 2 min.


**3.8 Third  
Amplification—PCR 3  
(Real-Time PCR)**

1. Transfer 27.2  $\mu\text{L}$  of each sample into a MicroAmp™ Optical 96-Well Reaction Plate.
2. Make a 1 in 50 dilution of SYBR Green diluted stock (see Subheading 2, item 19) by mixing 1  $\mu\text{L}$  of stock SYBR green and 49  $\mu\text{L}$  of water. This should be made up fresh immediately before use, since SYBR green is poorly soluble in water.




**Fig. 3** PCR 2 thermocycler program setup

3. Add 10  $\mu\text{L}$  of 5 $\times$  HF buffer, 5  $\mu\text{L}$  of SYBR green dilution, 1.25  $\mu\text{L}$  of dNTPs, 1  $\mu\text{L}$  of ROX, 2.5  $\mu\text{L}$  of P5 primer, 2.5  $\mu\text{L}$  of P7 primer, and 0.5  $\mu\text{L}$  of Phusion Polymerase to each sample and place the optical plate seal on the plate. For  $N$  samples (where  $N > 1$ ), a master mix should be prepared, containing 1.1  $N$  times the volumes above. The mix should be thoroughly mixed by pipetting or vortexing, and then 22.75  $\mu\text{L}$  of the mix should be added to each sample. The total sample volume at this stage should be 50  $\mu\text{L}$ . Apply the optical plate seal.
4. Briefly centrifuge the plate and then place into a real-time thermocycler, and amplify using the cycle program shown in Fig. 4. The number of cycles is dependent on how long the qPCR takes to reach the signal threshold. We routinely use a StepOne Thermocycler (ThermoFisher), but any machine can be used provided it is possible to follow the progress of the amplification in real time, and to stop the program when the signal reaches a predefined threshold. Some representative amplification plots are shown in Fig. 5.
5. Once the samples have reached the predefined threshold value, transfer the plate to a standard thermocycler for a final 5 min extension at 72  $^{\circ}\text{C}$  and then stop the thermocycler. Briefly centrifuge the plate.
6. Transfer each sample into a 96-Well PCR plate (the purification cannot be carried out in the qPCR plates as the ethanol wash volume exceeds the capacity of the well). Add 40  $\mu\text{L}$  of AMPure XP beads (at RT) to each sample, mix by pipetting up and down at least ten times (avoid creating bubbles). Seal and leave at RT for 5 min.
7. Purify following the procedure described in Subheading 3.5, steps 7–11.
8. Elute each sample in 30  $\mu\text{L}$  of water. Seal and leave at room temperature for 2 min.



**Fig. 4** PCR 3 real-time thermocycler program setup




**Fig. 5** Real-time PCR library amplification (PCR3, Subheading 3.8). Yellow and green lines represent alpha and beta TCR genes amplified from 1000 ng of lung tumor RNA

9. Briefly centrifuge the plate and place onto the plate magnet for 2 min.
10. Transfer 28  $\mu$ L of each purified library into a labeled 1.5 mL polypropylene low binding tube and store at  $-20^{\circ}\text{C}$  until required.

### 3.9 Library Quality Control and Sequencing (see Note 5)

1. The concentration of each DNA sample after amplification is quantified by spectroscopy (dsDNA high-sensitivity Qubit kit, ThermoFisher Scientific). Samples are also analyzed by micro-electrophoresis using a high-sensitivity D1000 TapeStation screen tape (Agilent). Typical profiles for libraries prepared from tumor and blood are shown in Fig. 6.
2. The final libraries are prepared by mixing samples with different indices. Improved sequencing is obtained if the final pooled library is further purified by electrophoresis. We use a Pippin Prep (Sage science), collecting fragments of between 350 and 750 base pairs (bp).
3. For Illumina MiSeq sequencing, each sample is present at 4 nM in the final library, and the library is then diluted, denatured, and a subsample is sequenced. Typically, 12 samples are run in parallel, yielding approximately one to two million reads per sample when using a v2 kit ( $2 \times 251$  bp paired end). However, greater depth can be achieved by running fewer samples per flow cell where needed. The final library concentration for loading is between 10 and 15 pM. 5–7% PhiX DNA at 14–20 pM is added to the library to increase diversity and improve cluster recognition. Denaturation and sequencing follows the standard Illumina protocols.



**Fig. 6** Electrophoretic (Tapestation) analysis of amplified TCR libraries prepared from 1000 ng RNA extracted from lung tumor samples. Successful library preparation yields a major peak of approximately 650 bp (solid arrow) as predicted from the combined size of the recombined TCR variable gene, together with the short sequence of constant region and various adaptors/indices. The peak molecular size as determined on the Tape station is used to convert the concentration from ng/ $\mu$ L to nM. In some samples (especially when there are few T cells in the tissue) the library includes additional bands at lower molecular weights (at approximately 400 bp, as demonstrated in panel B, shaded arrow). If the concentration of the 650 bp band is insufficient for sequencing (*see* Subheading 3.7), the library can be repurified and reamplified using the PCR3 protocol

4. For Illumina NextSeq sequencing, the final library is also prepared at 4 nM. Typically, at least 60 samples can be run on the flow cell, yielding 1–2 million reads per sample, when using the Mid-Output v2 300 cycle kit. Sample is loaded at 1 pM with 15–20% of PhiX DNA at 1.8 pM. Denaturation and sequencing follows standard Illumina protocols.

## 4 Notes

1. The protocol uses RNA rather than DNA as starting material, since this allows straightforward introduction of UMIs. The use of RNA also increases the likely coverage of the repertoire, since each cell contains several molecules of TCR mRNA. The method is potentially sensitive to changes in mRNA associated with T cell activation and differentiation. However, several studies have demonstrated that such changes are small and



transitory, and are therefore unlikely to have a major impact on the repertoire [28–31]. Unpublished experiments from our laboratory suggest that each TCR alpha or beta chain mRNA is present in at least 50 copies in each cell.

2. The ligation of an oligonucleotide to the 3' end of the cDNA permits introduction of UMIs before PCR amplification, and also avoids the need for multiplex PCR and the biases this can generate. This greatly increases the flexibility of the protocol because T cells from different species or gamma/delta TCRs—or indeed any target transcript—can be easily processed simply by changing the constant region primers. Although T4 RNA ligase is often described as having low efficiency for single-stranded DNA, we were unable to discover any publications with direct measurements of this efficiency. We therefore measured ligation efficiency using full-length cDNA extracted from Jurkat cells, and found it to be in the order of 10%. Thus, at least one in ten TCR cDNA molecules should be ligated after overnight ligation using this method.
3. We carried out the amplification protocol in three steps. All PCR steps were carried out using Phusion high-fidelity proof-reading polymerase. We observed that we could significantly increase efficiency by introducing a washing step after four cycles of PCR1. This was not due to inherent low efficiency of this PCR reaction, because amplification of an appropriate standard (a previously cloned TCR) showed PCR efficiencies >1.9. We speculate that residual oligonucleotide from the ligation step may remain after the first bead washing step and interfere with the amplification. Having this first round of amplification prior to separate alpha/beta processing also mitigates against losing lower frequency TCRs of one chain due to being sampled exclusively into the opposite chain's fraction. The third PCR was carried out using a qPCR SYBR Green protocol, so that amplification could be observed in real time. In this way, the amplification could be stopped when the amount of product reaches a pre-determined threshold, corresponding to a sufficient yield of DNA for sequencing. This avoids excessive amplification, which could bias against some rare TCR sequences in the starting pool, and minimizes the burden of erroneous sequence production.
4. PCR2 introduces several features required for subsequent sequencing on the Illumina platform, including the first sequencing primer SP1, an Illumina index for sequence multiplexing and the two Illumina anchor sequences P5 and P7. A random hexamer is introduced immediately downstream of SP1 to increase diversity at the beginning of the first sequence run, which greatly improves cluster identification. A second multiplexing index sequence is also introduced immediately 3' of the



- constant region. The option to introduce two independent indices is important when considering high-throughput experiments with many samples, which becomes even more important when using larger throughput machines such as the NextSeq, HiSeq, or NovaSeq series. Rotating through different indexes across multiple runs also protects against cross contamination, in which sequencing-compatible molecules can carry over from one run to a later one.
5. The cost of the protocol is an important consideration when large numbers of samples are to be processed. The current total cost of materials is in the order of £14 (approximately 16–18 Euros or US dollars) per sample, excluding sequencing. The most expensive component is the reverse transcriptase SuperScript III. We have not experimented with other reverse transcriptases but it is possible the total cost could be further reduced by using a different source of this enzyme.

---

## Acknowledgments

This research was funded by grants from CancerResearchUK, the UK MRC, the Rosetrees Trust, the Stoneygate Foundation, a grant to BC from Unilever PLC, and supported by the National Institute for Health Research UCL Hospitals Biomedical Research. JH was supported by an MRC studentship. K.J. is funded by the Sam Keen Foundation and UCL/Royal Marsden Hospital NIHR Biomedical Research Centres. We are grateful to the TRACERx consortium, funded by Cancer Research UK (<http://www.cruk-lungcentre.org/Research/TRACERx>) for giving us access to the tumor samples which the amplified TCR libraries illustrated in Figs. 5 and 6 were prepared.

---

## Appendix: The TRACERx Consortium

Name	Site/Institution
Jason Lester	Velindre Cancer Centre, Cardiff, Wales
Fiona Morgan	Cardiff & Vale University Health Board, Cardiff, Wales
Malgorzata Kornaszewska	Cardiff & Vale University Health Board, Cardiff, Wales
Richard Attanoos	Cardiff & Vale University Health Board, Cardiff, Wales
Haydn Adams	Cardiff & Vale University Health Board, Cardiff, Wales
Helen Davies	Cardiff & Vale University Health Board, Cardiff, Wales

Name	Site/Institution
Dean Fennell	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK & Leicester University Hospitals, Leicester, UK
John Le Quesne	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Apostolos Nakas	Leicester University Hospitals, Leicester, UK
Sridhar Rathinam	Leicester University Hospitals, Leicester, UK
William Monteiro	National Institute for Health Research Leicester Respiratory Biomedical Research Unit, Leicester, UK
Hilary Marshall	National Institute for Health Research Leicester Respiratory Biomedical Research Unit, Leicester, UK
Louise Nelson	Leicester University Hospitals, Leicester, UK
Kim Ryanna	Leicester University Hospitals, Leicester, UK
Alan Dawson	Leicester University Hospitals, Leicester, UK
Mohamad Tuffail	Leicester University Hospitals, Leicester, UK
Amrita Bajaj	Leicester University Hospitals, Leicester, UK
Jan Brozik	Leicester University Hospitals, Leicester, UK
Harriet Walter	Leicester University Hospitals, Leicester, UK
Jacqui Shaw	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Joan Riley	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Lindsay Primrose	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Luke Martinson	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Nicolas Carey	Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
Girija Anand	Barnet Hospital, Barnet, UK
Sajid Khan	Barnet Hospital, Barnet, UK
Gillian Price	Aberdeen Royal Infirmary, Aberdeen, UK
Marianne Nicolson	Aberdeen Royal Infirmary, Aberdeen, UK
Keith Kerr	Aberdeen Royal Infirmary, Aberdeen, UK
Shirley Palmer	Aberdeen Royal Infirmary, Aberdeen, UK
Hardy Remmen	Aberdeen Royal Infirmary, Aberdeen, UK
Joy Miller	Aberdeen Royal Infirmary, Aberdeen, UK

Name	Site/Institution
Keith Buchan	Aberdeen Royal Infirmary, Aberdeen, UK
Mahendran Chetty	Aberdeen Royal Infirmary, Aberdeen, UK
Lesley Gomersall	Aberdeen Royal Infirmary, Aberdeen, UK
Sara Lock	The Whittington Hospital NHS Trust, London, UK
Kayleigh Gilbert	The Whittington Hospital NHS Trust, London, UK
Babu Naidu	Heart of England NHS Foundation Trust, Birmingham, UK
Gerald Langman	Heart of England NHS Foundation Trust, Birmingham, UK
Simon Trotter	Heart of England NHS Foundation Trust, Birmingham, UK
Hollie Bancroft	Heart of England NHS Foundation Trust, Birmingham, UK
Amy Kerr	Heart of England NHS Foundation Trust, Birmingham, UK
Salma Kadiri	Heart of England NHS Foundation Trust, Birmingham, UK
Joanne Webb	Heart of England NHS Foundation Trust, Birmingham, UK
Gary Middleton	Heart of England NHS Foundation Trust, Birmingham, UK
Madava Djearaman	Heart of England NHS Foundation Trust, Birmingham, UK
Akshay Patel	Heart of England NHS Foundation Trust, Birmingham, UK
Yvonne Summers	University Hospital of South Manchester, Manchester, UK
Raffaele Califano	University Hospital of South Manchester, Manchester, UK
Paul Taylor	University Hospital of South Manchester, Manchester, UK
Rajesh Shah	University Hospital of South Manchester, Manchester, UK
Piotr Krysiak	University Hospital of South Manchester, Manchester, UK
Kendadai Rammohan	University Hospital of South Manchester, Manchester, UK
Eustace Fontaine	University Hospital of South Manchester, Manchester, UK

<b>Name</b>	<b>Site/Institution</b>
Richard Booton	University Hospital of South Manchester, Manchester, UK
Matthew Evison	University Hospital of South Manchester, Manchester, UK
Phil Crosbie	University Hospital of South Manchester, Manchester, UK
Stuart Moss	University Hospital of South Manchester, Manchester, UK
Juliette Novasio	University Hospital of South Manchester, Manchester, UK
Leena Joseph	University Hospital of South Manchester, Manchester, UK
Paul Bishop	University Hospital of South Manchester, Manchester, UK
Anshuman Chaturvedi	University Hospital of South Manchester, Manchester, UK
Anne Marie Quinn	University Hospital of South Manchester, Manchester, UK
Helen Doran	University Hospital of South Manchester, Manchester, UK
Felice Granato	University Hospital of South Manchester, Manchester, UK
Angela leek	Manchester Cancer Research Centre Biobank, Manchester, UK
Phil Harrison	Manchester Cancer Research Centre Biobank, Manchester, UK
Katrina Moore	Manchester Cancer Research Centre Biobank, Manchester, UK
Rachael Waddington	Manchester Cancer Research Centre Biobank, Manchester, UK
Fiona Blackhall	Christie NHS Foundation Trust, Manchester, UK
Jane Rogan	Manchester Cancer Research Centre Biobank, Manchester, UK
Elaine Smith	University Hospital of South Manchester, Manchester, UK
Katie Baker	Christie NHS Foundation Trust, Manchester, UK
Mathew Carter	Christie NHS Foundation Trust, Manchester, UK
Lynsey Priest	Christie NHS Foundation Trust, Manchester, UK
Matthew G Krebs	Christie NHS Foundation Trust, Manchester, UK
Colin Lindsay	Christie NHS Foundation Trust, Manchester, UK

Name	Site/Institution
Fabio Gomes	Christie NHS Foundation Trust, Manchester, UK
Caroline Dive	Manchester labs
Ged Brady	Manchester labs
Dominic Rothwell	Manchester labs
Sakshi Gulati	Manchester labs
Francesca Chemie	Manchester labs
Jonathan Tugwood	Manchester labs
Jackie Pierce	Manchester labs
David Lawrence	University College London Hospitals, London, UK
Martin Hayward	University College London Hospitals, London, UK
Nikolaos Panagiotopoulos	University College London Hospitals, London, UK
Robert George	University College London Hospitals, London, UK
Davide Patrini	University College London Hospitals, London, UK
Mary Falzon	University College London Hospitals, London, UK
Elaine Borg	University College London Hospitals, London, UK
Reena Khiroya	University College London Hospitals, London, UK
Charles Swanton	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK; Translational Cancer Therapeutics Laboratory, London Research Institute, London, UK
Mariam Jamal-Hanjani	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK
Gareth Wilson	The Francis Crick Institute, London, UK
Nicolai Juul Birkbak	The Francis Crick Institute, London, UK
Thomas Watkins	The Francis Crick Institute, London, UK
Nicholas McGranahan	The Francis Crick Institute, London, UK

Name	Site/Institution
Christopher Abbosh	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK
Rachel Rosenthal	The Francis Crick Institute, London, UK
Mickael Escudero	The Francis Crick Institute, London, UK
Aengus Stewart	The Francis Crick Institute, London, UK
Andrew Rowan	The Francis Crick Institute, London, UK
Crispin Hiley	The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK
Jacki Goldman	The Francis Crick Institute, London, UK
Asia Ahmed	University College London Hospitals, London, UK
Magali Taylor	University College London Hospitals, London, UK
Junaid Choudhary	University College London Hospitals, London, UK
Penny Shaw	
Raju Veeriah	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK
Justyna Czyzewska-Khan	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK
Diana Johnson	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK
Joanne Laycock	Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK
Marcin Skrzypski	
Robert Hynds	
Kroopa Joshi	
Assma Ben Aissa	
Yien Ning Sophia Wong	
Andy Georgiou	
Mariana Werner Sunderland	
James Reading	

Name	Site/Institution
Sergio Quezada	
Carmella Beastall	University College London Cancer Institute, London, UK
Nagina Mangal	University College London Cancer Institute, London, UK
Karl Peggs	
Teresa Marafioti	
Sam Janes	University College London Hospitals, London, UK
Martin Forster	University College London Hospitals, London, UK
Tanya Ahmad	University College London Hospitals, London, UK
Siow Ming Lee	University College London Hospitals, London, UK
Peter van Loo	
Javier Herrero	The Francis Crick Institute, London, UK
John Hartley	
Richard Kevin Stone	The Francis Crick Institute, London, UK
Tamara Denner	The Francis Crick Institute, London, UK
Emma Nye	The Francis Crick Institute, London, UK
Sophia Ward	The Francis Crick Institute, London, UK
Emilia Lim	The Francis Crick Institute, London, UK
Maise Al-Bakir	
Dawn Carnell	University College London Hospitals, London, UK
Ruheena Mendes	University College London Hospitals, London, UK
Jeremy George	University College London Hospitals, London, UK
Neal Navani	University College London Hospitals, London, UK
Dionysis Papadatos-Pastos	University College London Hospitals, London, UK
Marco Scarci	University College London Hospitals, London, UK

Name	Site/Institution
Pat Gorman	
Helen Lowe	
Leah Ensell	
David Moore	
Dhruva Biswas	University College London Cancer Institute, London, UK
Roberto Salgado	Department of Pathology, GZA-ZNA Antwerp, Belgium
Maryam Razaq	
Jerome Nicod	
Stephan Beck	
Saioa Lopez	Nickys lab
Ariana Huebner	Nickys lab
Michelle Dietzen	Nickys lab
Thanos Mourikis	Nickys lab
Mairead MacKenzie	Independent Cancer Patients Voice
Maggie Wilcox	Independent Cancer Patients Voice
Harriet Bell	Cancer Research UK & UCL Cancer Trials Centre, London, UK
Allan Hackshaw	Cancer Research UK & UCL Cancer Trials Centre, London, UK
Yenting Ngai	Cancer Research UK & UCL Cancer Trials Centre, London, UK
Sean Smith	Cancer Research UK & UCL Cancer Trials Centre, London, UK
Nicole Gower	Cancer Research UK & UCL Cancer Trials Centre, London, UK
Christian Ottensmeier	University Hospital Southampton NHS Foundation Trust
Serena Chee	University Hospital Southampton NHS Foundation Trust
Benjamin Johnson	University Hospital Southampton NHS Foundation Trust
Aiman Alzetani	University Hospital Southampton NHS Foundation Trust
Emily Shaw	University Hospital Southampton NHS Foundation Trust
Eric Lim	Royal Brompton and Harefield NHS Foundation Trust



<b>Name</b>	<b>Site/Institution</b>
Paulo De Sousa	Royal Brompton and Harefield NHS Foundation Trust
Monica Tavares Barbosa	Royal Brompton and Harefield NHS Foundation Trust
Andrew Nicholson	Royal Brompton and Harefield NHS Foundation Trust
Alex Bowman	Royal Brompton and Harefield NHS Foundation Trust
Simon Jordan	Royal Brompton and Harefield NHS Foundation Trust
Alexandra Rice	Royal Brompton and Harefield NHS Foundation Trust
Hilgardt Raubenheimer	Royal Brompton and Harefield NHS Foundation Trust
Harshil Bhayani	Royal Brompton and Harefield NHS Foundation Trust
Morag Hamilton	Royal Brompton and Harefield NHS Foundation Trust
Natalie Mensah	Royal Brompton and Harefield NHS Foundation Trust
Lyn Ambrose	Royal Brompton and Harefield NHS Foundation Trust
Anand Devaraj	Royal Brompton and Harefield NHS Foundation Trust
Hemangi Chavan	Royal Brompton and Harefield NHS Foundation Trust
Toyin Adefila-Ideozu	Royal Brompton and Harefield NHS Foundation Trust
Sofina Begum	Royal Brompton and Harefield NHS Foundation Trust
Henriette Klein	Royal Brompton and Harefield NHS Foundation Trust
Aleksander Mani	Royal Brompton and Harefield NHS Foundation Trust
Soraia Carvalho	Royal Brompton and Harefield NHS Foundation Trust
Daniel Kaniu	Royal Brompton and Harefield NHS Foundation Trust
Cristina Realengo	Royal Brompton and Harefield NHS Foundation Trust

<b>Name</b>	<b>Site/Institution</b>
Mpho Malima	Royal Brompton and Harefield NHS Foundation Trust
Sarah Booth	Royal Brompton and Harefield NHS Foundation Trust
Kelvin Lau	Barts Health NHS Trust
Michael Sheaff	Barts Health NHS Trust
Peter Schmid	Barts Health NHS Trust
Louise Lim	Barts Health NHS Trust
John Conibear	Barts Health NHS Trust
Veni Ezhil	Ashford and St. Peter's Hospitals NHS Foundation Trust
Vineet Prakash	Ashford and St. Peter's Hospitals NHS Foundation Trust
Sarah Danson	Sheffield Teaching Hospitals NHS Foundation Trust
Jonathan Bury	Sheffield Teaching Hospitals NHS Foundation Trust
John Edwards	Sheffield Teaching Hospitals NHS Foundation Trust
Jennifer Hill	Sheffield Teaching Hospitals NHS Foundation Trust
Sue Matthews	Sheffield Teaching Hospitals NHS Foundation Trust
Yota Kitsanta	Sheffield Teaching Hospitals NHS Foundation Trust
Jagan Rao	Sheffield Teaching Hospitals NHS Foundation Trust
Sara Tenconi	Sheffield Teaching Hospitals NHS Foundation Trust
Laura Soggi	Sheffield Teaching Hospitals NHS Foundation Trust
Kim Suvarna	Sheffield Teaching Hospitals NHS Foundation Trust
Faith Kibutu	Sheffield Teaching Hospitals NHS Foundation Trust
Michael Agyemang	Sheffield Teaching Hospitals NHS Foundation Trust
Patricia Fisher	Sheffield Teaching Hospitals NHS Foundation Trust

Name	Site/Institution
Robin Young	Sheffield Teaching Hospitals NHS Foundation Trust
Michael Shackcloth	Liverpool Heart and Chest Hospital NHS Foundation Trust
John Gosney	Liverpool Heart and Chest Hospital NHS Foundation Trust
Sarah Feeney	Liverpool Heart and Chest Hospital NHS Foundation Trust
Julius Asante-Siaw	Liverpool Heart and Chest Hospital NHS Foundation Trust
Teresa Light	The Princess Alexandra Hospital NHS Trust
Tracey Horey	The Princess Alexandra Hospital NHS Trust
Dr. Dionysis Papadatos-Pastos	The Princess Alexandra Hospital NHS Trust
Dr. Peter Russell	The Princess Alexandra Hospital NHS Trust
Kevin G. Blyth	NHS Greater Glasgow and Clyde
Craig Dick	NHS Greater Glasgow and Clyde
Alan Kirk	Golden Jubilee National Hospital
Andrew Kidd	NHS Greater Glasgow and Clyde

## References

1. Heather JM, Chain B (2016) The sequence of sequencers: The history of sequencing DNA. *Genomics* 107:1–8
2. Pasetto A, Gros A, Robbins PF et al (2016) Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. *Cancer Immunol Res* 4:734–743
3. Gros A, Robbins PF, Yao X et al (2014) PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. *J Clin Invest* 124:2246–2259
4. Gerlinger M, Quezada SA, Peggs KS et al (2013) Ultra-deep T-cell receptor sequencing reveals the complexity and intratumour heterogeneity of T-cell clones in renal cell carcinomas. *J Pathol* 231:424–432
5. Chen Z, Zhang C, Pan Y et al (2016) T cell receptor  $\beta$ -chain repertoire analysis reveals intra-tumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma. *J Pathol* 239:450–458
6. Reuben A, Gittelman R, Gao J et al (2017) TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. *Cancer Discov* 7:1088–1097
7. Emerson RO, Sherwood AM, Rieder MJ et al (2013) High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. *J Pathol* 231:433–440
8. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 515:568–571
9. Snyder A, Nathanson T, Funt SA et al (2017) Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. *PLoS Med* 14:e1002309
10. Robert L, Tsoi J, Wang X et al (2014) CTLA4 blockade broadens the peripheral T-cell receptor repertoire. *Clin Cancer Res* 20:2424–2432

11. Cha E, Klinger M, Hou Y et al (2014) Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. *Sci Transl Med* 6:238ra70
12. Kvistborg P, Philips D, Kelderman S et al (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8<sup>+</sup> T cell response. *Sci Transl Med* 6:254ra128
13. Riaz N, Havel JJ, Makarov V et al (2017) Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. *Cell* 171:934–949.e15
14. Wu D, Sherwood A, Fromm JR et al (2012) High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. *Sci Transl Med* 4:134ra63
15. Logan AC, Gao H, Wang C et al (2011) High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. *Proc Natl Acad Sci* 108:21194–21199
16. Hou X-L, Wang L, Ding Y-L et al (2016) Current status and recent advances of next generation sequencing techniques in immunological repertoire. *Genes Immun* 17:153–164
17. Robins H (2013) Immunosequencing: applications of immune repertoire deep sequencing. *Curr Opin Immunol* 25:646–652
18. Six A, Mariotti-Ferrandiz ME, Chaara W et al (2013) The past, present, and future of immune repertoire biology - the rise of next-generation repertoire analysis. *Front Immunol* 4:1–16
19. Heather JM, Ismail M, Oakes T, et al (2017) High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities. *Brief Bioinform* bbw138
20. Thomas N, Heather J, Ndifon W et al (2013) Decombinator: a tool for fast, efficient gene assignment in T-cell receptor sequences using a finite state machine. *Bioinformatics* 29:542–550
21. Oakes T, Heather JM, Best K et al (2017) Quantitative characterization of the T cell receptor repertoire of naïve and memory subsets using an integrated experimental and computational pipeline which is robust, economical, and versatile. *Front Immunol* 8:1267
22. Weinstein JA, Jiang N, White RA et al (2009) High-throughput sequencing of the zebrafish antibody repertoire. *Science* 324:807–810
23. Shugay M, Britanova OV, Merzlyak EM et al (2014) Towards error-free profiling of immune repertoires. *Nat Methods* 11:653–655
24. Mamedov IZ, Britanova OV, Zvyagin IV et al (2013) Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling. *Front Immunol* 4:1–10
25. Best K, Oakes T, Heather JM et al (2015) Computational analysis of stochastic heterogeneity in PCR amplification efficiency revealed by single molecule barcoding. *Sci Rep* 5:14629
26. Jamal-Hanjani M, Hackshaw A, Ngai Y et al (2014) Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. *PLoS Biol* 12:e1001906
27. Jamal-Hanjani M, Wilson GA, McGranahan N et al (2017) Tracking the evolution of non-small-cell lung cancer. *N Engl J Med* 376:2109–2121
28. Gallard A, Foucras G, Coureau C et al (2002) Tracking T cell clonotypes in complex T lymphocyte populations by real-time quantitative PCR using fluorogenic complementarity-determining region-3-specific probes. *J Immunol Methods* 270:269–280
29. Lindsten T, June CH, Thompson CB (1988) Transcription of T cell antigen receptor genes is induced by protein kinase C activation. *J Immunol* 141:1769–1774
30. Paillard F, Sterkers G, Vaquero C (1990) Transcriptional and post-transcriptional regulation of TcR, CD4 and CD8 gene expression during activation of normal human T lymphocytes. *EMBO J* 9:1867–1872
31. Paillard F, Sterkers G, Vaquero C (1992) Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes. *Biochem Biophys Res Commun* 186:603–611